Ahmann D L, Scanlon P W, Bisel H F, Edmonson J H, Frytak S, Payne W S, O'Fallon J R, Hahn R G, Ingle J N, O'Connell M J, Rubin J
Lancet. 1978 Apr 29;1(8070):893-6. doi: 10.1016/s0140-6736(78)90678-5.
172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P.A.M.) or a combination of cyclophosphamide, 5-fluorouracil, and prednisone (C.F.P.) with and without radiotherapy. Tumours recurred significantly more frequently and mortality tended to be higher in P.A.M.-treated patients than in patients on other treatment. The interval between surgery and disease recurrence was significantly shorter for P.A.M.-treated premenopausal but not postmenopausal patients than for patients of equivalent menstrual status treated with C.F.P. with or without radiation. The associations in premenopausal patients between the mode of treatment and both survival and the disease-free interval were significant before and after adjustment for variations between the treatment groups in the number of involved lymph nodes and the size of the primary tumour.
172例因乳腺癌接受乳房切除术的患者接受了重复辅助化疗，化疗药物为苯丙氨酸氮芥（P.A.M.）或环磷酰胺、5-氟尿嘧啶和泼尼松的联合用药（C.F.P.），部分患者还接受了放疗。与接受其他治疗的患者相比，接受P.A.M.治疗的患者肿瘤复发明显更频繁，死亡率也往往更高。接受P.A.M.治疗的绝经前患者（而非绝经后患者）手术至疾病复发的间隔时间明显短于接受C.F.P.治疗（无论是否接受放疗）的同等月经状态患者。在调整治疗组之间受累淋巴结数量和原发肿瘤大小的差异后，绝经前患者的治疗方式与生存率和无病间期之间的关联在调整前后均具有显著性。
